Moneycontrol PRO
glenmark pharmaceuticals
Jump to
  • Glenmark gets USFDA nod to market generic medication March 20, 2023 10:20 AM IST

    Glenmark gets USFDA nod to market generic medication

    The company has received nod from the US Food & Drug Administration (USFDA) for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, the Mumbai-based drug maker said in a statement.

  • Glenmark Pharma receives USFDA approval for generic antibiotic drug March 14, 2023 12:49 PM IST

    Glenmark Pharma receives USFDA approval for generic antibiotic drug

    The company has received final approval from the US Food & Drug Administration (USFDA) for Clindamycin Hydrochloride Capsules, a generic version of Pfizer's Cleocin capsules, Glenmark Pharma said in a statement.

  • Glenmark and Cediprof announce exclusive distribution agreement in US March 09, 2023 10:18 AM IST

    Glenmark and Cediprof announce exclusive distribution agreement in US

    Glenmark said it expects to commence distribution of the product in the US during the second half of 2023. The drug is indicated for treatment of attention deficit hyperactivity disorder.

  • Hot Stocks | Bet on Glenmark Pharma, ABB India, Siemens for double-digit returns February 23, 2023 07:10 AM IST

    Hot Stocks | Bet on Glenmark Pharma, ABB India, Siemens for double-digit returns

    Glenmark Pharma is on the verge of a breakout from a long consolidation period. The stock has also witnessed a fresh, built-up position in the F&O space.

  • Accumulate Glenmark Pharmaceuticals; target of Rs 460: Prabhudas Lilladher February 15, 2023 08:53 PM IST

    Accumulate Glenmark Pharmaceuticals; target of Rs 460: Prabhudas Lilladher

    Prabhudas Lilladher recommended accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 460 in its research report dated February 14, 2023.

  • Glenmark Pharma Q3 PAT rises 21.3% to Rs 290.8 crore February 10, 2023 10:26 PM IST

    Glenmark Pharma Q3 PAT rises 21.3% to Rs 290.8 crore

    Consolidated revenue was at Rs 3,463.9 crore, as against Rs 3,173.4 crore, up 9.2 per cent, Glenmark Pharmaceuticals said.

  • Glenmark introduces medication to prevent chemotherapy-induced nausea January 23, 2023 11:36 AM IST

    Glenmark introduces medication to prevent chemotherapy-induced nausea

    The company has introduced IV injection formulation Akynzeo IV in a fixed dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg) and is available as a ready-to-dilute IV injection, the Mumbai-based drug maker said in a statement.

  • Glenmark launches drug to treat heart failure January 17, 2023 02:20 PM IST

    Glenmark launches drug to treat heart failure

    The prescription drug has been launched under brand 'Sacu V' and is priced at Rs 19 per tablet for a dose of 50mg (sacubitril 24mg + valsartan 26mg), Rs 35 per tablet for a dose of 100mg (sacubitril 49mg + valsartan 51mg), and Rs 45 per tablet for a dose of 200mg (sacubitril 97mg + valsartan 103 mg), Glenmark said in a regulatory filing.

  • Glenmark Pharmaceuticals launches generic version of diuretic Bumetanide injection January 10, 2023 10:58 AM IST

    Glenmark Pharmaceuticals launches generic version of diuretic Bumetanide injection

    In a statement the company said Glenmark Pharmaceuticals Inc., USA (Glenmark) launched Bumetanide Injection of strengths of 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multi-dose vials.

  • Trade Spotlight | What should you do with Glenmark Pharma, Biocon, LTIMindtree on Thursday? December 22, 2022 06:49 AM IST

    Trade Spotlight | What should you do with Glenmark Pharma, Biocon, LTIMindtree on Thursday?

    Biocon shares gained 3.5 percent at Rs 271 and formed long bullish candle on the daily charts with robust volumes. Also there was Morning Star kind of pattern formation, which is generally called as a bullish reversal pattern formed in an downtrend.

  • Glenmark Pharma launches combination drug for diabetic patients December 21, 2022 10:18 AM IST

    Glenmark Pharma launches combination drug for diabetic patients

    This fixed-dose combination offers patients with Type 2 diabetes the convenience of once daily dosing to improve their glycemic control. It is priced at Rs 14.90 per day, thereby reducing the daily cost of therapy by 40 per cent, making it more affordable to the masses, the company said in a statement.

  • Hold Glenmark Pharmaceuticals; target of Rs 470: ICICI Direct November 22, 2022 11:34 AM IST

    Hold Glenmark Pharmaceuticals; target of Rs 470: ICICI Direct

    ICICI Direct recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 470 in its research report dated November 21, 2022.

  • Accumulate Glenmark Pharmaceuticals; target of Rs 460: Prabhudas Lilladher November 21, 2022 03:19 PM IST

    Accumulate Glenmark Pharmaceuticals; target of Rs 460: Prabhudas Lilladher

    Prabhudas Lilladher recommended accumulate rating on Glenmark Pharmaceuticals with a target price of Rs 460 in its research report dated November 19, 2022.

  • Glenmark gets USFDA nod for generic medication November 02, 2022 12:48 PM IST

    Glenmark gets USFDA nod for generic medication

    The company has received final approval from the US Food and Drug Administration (USFDA) for the product which is a generic version of Horizon Therapeutics' Buphenyl, the Mumbai-based drug maker said in a statement.

  • USFDA issues import alert on Glenmark Pharma's Baddi plant October 26, 2022 09:59 PM IST

    USFDA issues import alert on Glenmark Pharma's Baddi plant

    The drugs produced at the Baddi unit can now be detained without physical examination.

  • Glenmark Pharma launches drug for diabetic patients with comorbidities October 20, 2022 12:27 PM IST

    Glenmark Pharma launches drug for diabetic patients with comorbidities

    The Mumbai-based drug maker said it has become the first company to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed-dose combination for the treatment of adult patients with type 2 diabetes.

  • Glenmark launches drug to treat patients with insulin-resistant diabetes October 06, 2022 12:36 PM IST

    Glenmark launches drug to treat patients with insulin-resistant diabetes

    The Mumbai-based drug firm has launched the medication under the brand name LOBG and is priced at around Rs 10 per tablet.

  • Glenmark Pharma gets approval from Health Canada for nasal spray Ryaltris September 23, 2022 11:19 AM IST

    Glenmark Pharma gets approval from Health Canada for nasal spray Ryaltris

    Health Canada granted approval to partner Bausch Health Companies Inc and Glenmark Specialty SA, a subsidiary of the company, for Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray), Glenmark Pharmaceuticals said in a statement.

  • Hold Glenmark Pharmaceuticals; target of Rs 440: ICICI Direct August 17, 2022 03:19 PM IST

    Hold Glenmark Pharmaceuticals; target of Rs 440: ICICI Direct

    ICICI Direct recommended hold rating on Glenmark Pharmaceuticals with a target price of Rs 440 in its research report dated August 16, 2022.

  • Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher July 08, 2022 05:36 PM IST

    Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher

    Net Sales are expected to decrease by 4.2 percent Y-o-Y (down 5.9 percent Q-o-Q) to Rs 2,841.6 crore, according to Prabhudas Lilladher.

  • Glenmark Pharmaceuticals acquires certain OTC drugs from Wockhardt in US June 28, 2022 10:49 AM IST

    Glenmark Pharmaceuticals acquires certain OTC drugs from Wockhardt in US

    The acquisition by the company's fully-owned subsidiary Glenmark Pharmaceuticals Inc, USA includes the approved abbreviated new drug applications (ANDAs) for famotidine tablets, 10 mg and 20 mg used to treat and prevent ulcers in the stomach and intestine, the company said in a statement.

  • Glenmark Pharma launches asthma drug Indamet June 16, 2022 10:17 AM IST

    Glenmark Pharma launches asthma drug Indamet

    The Mumbai-based drug major has launched - Indacaterol + Mometasone FDC under the brand name Indamet.

  • Glenmark launches fixed-dose combination for diabetic patients April 25, 2022 11:18 AM IST

    Glenmark launches fixed-dose combination for diabetic patients

    Glenmark has launched this FDC under the brand name Zita Plus Pio, which contains Teneligliptin (20 mg) and Pioglitazone (15 mg), to be taken once a day, the company said in a statement.

  • Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher April 14, 2022 04:52 PM IST

    Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 5.1 percent Y-o-Y (down 5.3 percent Q-o-Q) to Rs 3,006.1 crore, according to Prabhudas Lilladher.

  • Glenmark Pharma shares gain on DCGI nod to clinical trial of 'novel' small molecule April 11, 2022 10:46 AM IST

    Glenmark Pharma shares gain on DCGI nod to clinical trial of 'novel' small molecule

    Glenmark will initiate Phase 1 clinical trial in India by June 2022 for its small molecule, GRC 54276, a hematopoietic progenitor kinase 1 (HPK1) inhibitor